REMARKS

I. Amendments

By this amendment, claims 9-12 and 16 have been amended, new claims 23-30 have been

added and claims 1-8, 13-15, 17 and 19-22 have been cancelled.

Typographical and grammatical errors have also been corrected throughout the

specification.

This amendment adds no new matter to the specification. Support for this amendment is

found in the specification and claims as filed.

No amendment of inventorship is necessitated by this amendment.

II. Conclusion

Consideration and allowance of the claims as amended is requested. Should the

Examiner believe that a conference with Applicants' attorney would advance prosecution of this

application, the Examiner is respectfully requested to call Applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: November 20, 2003

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants

Customer No. 23,115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA